AbbVie (NYSE:ABBV) Releases Q4 2026 Earnings Guidance

AbbVie (NYSE:ABBV) updated its fourth quarter 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 3.830-3.870 for the period, compared to the consensus estimate of 3.890. The company issued revenue guidance of $18.4 billion, compared to the consensus revenue estimate of $18.3 billion. AbbVie also updated its FY 2026 guidance to 13.950-13.990 EPS.

Analyst Ratings Changes

ABBV has been the topic of a number of recent analyst reports. Royal Bank Of Canada upped their price target on AbbVie from $280.00 to $330.00 and gave the stock an “outperform” rating in a research report on Monday. Citigroup raised their price target on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Morgan Stanley raised their target price on AbbVie from $310.00 to $346.00 and gave the stock an “overweight” rating in a research note on Monday. The Goldman Sachs Group lifted their target price on AbbVie from $258.00 to $294.00 and gave the stock a “neutral” rating in a report on Friday, October 23rd. Finally, Cantor Fitzgerald increased their price target on shares of AbbVie from $290.00 to $325.00 and gave the stock an “overweight” rating in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $294.67.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $290.02 on Tuesday. The business’s 50 day moving average price is $269.81 and its 200-day moving average price is $237.57. AbbVie has a 1 year low of $190.75 and a 1 year high of $298.74. The firm has a market capitalization of $512.41 billion, a price-to-earnings ratio of 49.74, a price-to-earnings-growth ratio of 1.31 and a beta of 0.24.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping the consensus estimate of $3.73 by $0.09. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company had revenue of $17.40 billion during the quarter, compared to analyst estimates of $17.32 billion. During the same period in the previous year, the business earned $1.86 EPS. AbbVie’s quarterly revenue was up 10.3% on a year-over-year basis. On average, sell-side analysts expect that AbbVie will post 13.92 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be given a $1.82 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Friday, January 15th. AbbVie’s dividend payout ratio (DPR) is presently 119.10%.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie raised its fiscal 2026 adjusted EPS outlook to $13.95-$13.99, above the prior consensus midpoint, and forecast revenue of $67.8 billion, ahead of the $67.6 billion consensus. Growth from Skyrizi, Rinvoq and neuroscience products is helping offset Humira’s decline. ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
• Positive Sentiment: Multiple analysts raised their price targets following AbbVie’s strong third-quarter results, including RBC to $330, Cantor Fitzgerald to $325, Canaccord Genuity to $338, Leerink Partners to $342 and Morgan Stanley to $346. The firms maintained bullish ratings. Analysts Increase Forecasts on AbbVie
• Positive Sentiment: AbbVie expanded a global license agreement with Brise Pharmaceuticals for next-generation migraine therapies. The deal could be worth up to approximately $757 million and follows positive Phase 3 migraine data published in The Lancet Neurology. AbbVie License Deal With Brise
• Positive Sentiment: AbbVie won a lawsuit challenging certain drug-price-control actions by the U.S. Department of Health and Human Services, potentially reducing regulatory and pricing pressure. AbbVie Wins Drug Price Control Lawsuit
• Neutral Sentiment: Allergan Aesthetics will present nine research abstracts at ASDS 2026, covering aesthetic treatment after medical weight loss, BOTOX Cosmetic and investigational trenibotulinumtoxinE. The event supports AbbVie’s long-term aesthetics pipeline but is unlikely to materially affect near-term earnings. Allergan Aesthetics ASDS 2026 Research
• Negative Sentiment: AbbVie’s fourth-quarter EPS guidance of $3.83-$3.87 is below the $3.89 consensus estimate, despite revenue guidance of $18.4 billion exceeding expectations. The modest earnings shortfall may be the clearest near-term pressure on the shares.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.